

1 **Cooke, Richard <r.cooke@aston.ac.uk>Cooke, Richard**  
2 **<r.cooke@aston.ac.uk>Development of a prescribing indicator for**  
3 **objective quantification of antibiotic usage in secondary care.**

4 Chris Curtis<sup>1</sup>, John Marriott<sup>2</sup> and Chris Langley<sup>2\*</sup>. <sup>1</sup>Pharmacy Department, Queen's  
5 Hospital, Burton, DE13 0RB, England and <sup>2</sup> Pharmacy Department, Aston University,  
6 Aston Triangle, Birmingham, B4 7ET, England.

7  
8 **Abstract**

9  
10 Objectives

11 To compare the recognised Defined Daily Dose per 100 bedday measure (DDD/100  
12 bedday) with the Defined Daily Dose per Finished Consultant Episode (DDD/FCE) in  
13 a group of hospitals with a variety of medicines management strategies.

14 **To compare antibiotic usage using the above indicators in hospitals with and without**  
15 **electronic prescribing systems.**

16  
17 Methods

18 Twelve hospitals were used in the study. Nine hospitals were selected and split into  
19 three cohorts (three high-scoring, three medium-scoring and three low-scoring) by  
20 their 2001 Medicines Management self-assessment scores (MMAS). An additional  
21 cohort of three electronic prescribing hospitals was included for comparison. MMAS  
22 were compared to Antibiotic Management Scores (AMS) developed from a  
23 questionnaire relating specifically to control of antibiotics. FCEs and occupied  
24 beddays were obtained from published statistics and statistical analysis of the  
25 DDD/100 beddays and DDD/FCE were carried out using SPSS.

## Antibiotic prescribing indicators

1

### 2 Results

3 The DDD/100 beddays varied from 81.33 to 189.37 whilst the DDD/FCE varied from  
4 2.88 to 7.43. The two indicators showed a high degree of correlation  $r = 0.74$ .

5 MMAS were from 9 to 22 (possible range 0 to 23) and the AMS from 2 to 13  
6 (possible range 0 to 22). The two scores showed a high degree of correlation  $r = 0.74$ .

7 No correlation was established between either indicator and either score.

8

### 9 Conclusions

10 The WHO indicator for medicines utilisation, DDD/100 beddays, exhibited the same  
11 level of conformity as that exhibited from the use of the DDD/FCE indicating that the  
12 DDD/FCE is a useful additional indicator for identifying hospitals which require  
13 further study.

14

15 The MMAS can be assumed to be an accurate guide to antibiotic medicines  
16 management controls.

17

18 No relationship has been found between a high degree of medicines management  
19 control and the quantity of antibiotic prescribed.

20

### 21 Keywords

22 Antibiotic usage, Defined Daily Dose, prescribing indicator, secondary care.

23

24 \*Corresponding author. Tel: +44 (0)121 359 3611; Fax: +44 (0)121 359 0733; E-  
25 mail: c.a.langley@aston.ac.uk.

26

1 **Introduction**

2 It has been estimated<sup>1</sup> that twenty per cent of medicines expenditure in England  
3 occurs in secondary care. However, there is little aggregated data relating to the use of  
4 medicines in this sector. Pilot work,<sup>2</sup> found that during the period between January  
5 1997 and December 1998, antibiotics accounted for nineteen per cent of the total  
6 expenditure on medicines in secondary care, which was the highest spend of all  
7 categories of medicinal product. Participants within the study also highlighted that  
8 there was a need for a suitable indicator to facilitate benchmarking between hospitals.

9

10 The emergence of ‘evidence based practice’ during the NHS policy reforms of the  
11 1990s was part of the change to create a culture in which clinical governance drives  
12 individual hospital practitioners to examine their practice and compare it with their  
13 peers. Pharmaceutical care, ‘the responsible provision of drug therapy for the purpose  
14 of achieving definite outcomes that improve a patient’s quality of life’<sup>3</sup> defines the  
15 scope of pharmaceutical responsibility in the use of medicines. This was  
16 supplemented by the ‘medicines management’ concept,<sup>4</sup> which developed the theme  
17 of systems to control medicines usage from procurement, managed entry onto a  
18 hospital formulary through to prescribing review and use of clinical guidelines. In  
19 order to optimise the use of medicines, it is vital that therapeutic categories of  
20 medicines where there is high-volume and high-cost are reviewed. It has been  
21 established that antibiotics are often both high-volume and high-cost. In addition, it  
22 has been demonstrated<sup>5</sup> that a large percentage of antibiotic use in hospitals is  
23 inappropriate.

24

## Antibiotic prescribing indicators

1 Clearly, there is a requirement for multi-centre clinical audit of antibiotic usage.  
2 However, in order to benchmark the use of antibiotics across the full spectrum of  
3 secondary care settings, a robust measure is needed which is independent of  
4 workload, in order that comparisons can be made. The UK Department of Health has  
5 recently allocated funding for each English hospital to use for promoting 'prudent use  
6 of antibiotics'.<sup>6</sup> This initiative will enable work to commence to improve targeted  
7 clinical pharmacy initiatives related to antibiotic use and also to begin to address  
8 collection of data from hospitals.

9

10 A large amount of therapeutic guidance<sup>7-12</sup> has been published, which focuses on  
11 antibiotic resistance and the use of antibiotics in medicine. Issues examined include  
12 the use of formularies within hospitals, the process by which antibiotics are prescribed  
13 by junior doctors, sensitivity testing and the surveillance of resistant organisms. One  
14 report<sup>13</sup> concluded that there was a lack of data on antimicrobial use in hospitals and  
15 that hospitals should install computerised systems for patient specific prescribing.

16

17 The European Society for Clinical Microbiology and Infectious Disease (ESCMID)  
18 established a study group on antibiotic policies (ESGAP) which in turn created a  
19 number of sub-groups to develop strategy related to the stewardship of antibiotics  
20 within European hospitals. This group produced a number of recommendations<sup>14</sup>  
21 which include a commendation that 'measurement of antibiotic consumption should  
22 be performed with regular benchmarking of figures and discussion between  
23 prescribers, pharmacists and infection specialists'.

24

## Antibiotic prescribing indicators

1 The purpose of any indicator of prescribing is to enable comparisons to be made over  
2 time. The comparison may be between individual prescribers, wards, specialties,  
3 hospitals or geographical groups of hospitals. Measures are not definitive but act as a  
4 focus for the commencement of review and should act as a stimulus for change.

5

6 The need for an international classification system for drugs has been recognised for  
7 many years.<sup>15</sup> The Anatomical Therapeutic Chemical System (ATC), was developed  
8 by the Norwegian Medicinal Depot, in Oslo, by modification of an existing system  
9 that had been used by pharmaceutical market researchers in Europe. In addition to a  
10 robust classification system it was necessary to develop a unit of measurement. The  
11 Defined Daily Dose (DDD) was developed, also by the Norwegian Medicinal Depot  
12 as a unit of measurement for use in drug utilisation studies. The ATC/DDD system,  
13 was recommended for international drug utilisation studies by the World Health  
14 Organisation (WHO) in 1981. The purpose of the ATC/DDD system is to act as a tool  
15 for drug utilisation research so that the quality of drug usage will improve.

16

17 The DDD is defined<sup>16</sup> as ‘the assumed average maintenance dose per day for a drug  
18 used for its main indication in adults’. A DDD is only assigned when a compound has  
19 been given an ATC code. All of the ATC codes and DDD data are published in the  
20 ATC Index.<sup>17</sup> The DDD is not a reflection of a prescribed or recommended daily  
21 dose. It represents a unit of measurement to enable researchers to identify trends in  
22 consumption of medicines and to compare the exposure to specific medicines of  
23 population groups. The DDD is a compromise in that it is based on a review of doses  
24 used in a variety of countries. The DDD will normally be associated with a

## Antibiotic prescribing indicators

1 denominator to correct for workload variations. For hospital in-patients the number of  
2 DDDs per 100 beddays is normally used.

3

4 A study of the DDD system<sup>18</sup> compared the approach of Europeans to undertaking  
5 drug utilisation review with that of the North Americans which has focussed more on  
6 review of individual prescribers and individual drug regimens in order to optimise  
7 patient treatments.

8

9 This study concluded that the DDD system would serve as a valuable additional tool  
10 for drug utilisation studies. A further study carried out to evaluate DDD  
11 methodology<sup>19</sup> concluded that calculation of the DDD was a valuable first step in  
12 measuring total drug use in a population, but that for more precise estimates of drug  
13 use, other techniques would also be required.

14

15 An antibiotic usage measure developed in 1998 within our group<sup>20</sup> has been applied  
16 previously to the usage of quinolone antibiotics. In order to more fully evaluate the  
17 usefulness of this measure as a tool to compare antibiotic utilisation, the present study  
18 compares the recognised DDD/100 bedday measure with the DDD/FCE in a group of  
19 hospitals with a variety of medicines management strategies.

20

### 21 **Materials and method**

22 Four cohorts of three hospitals were used as data collection sites. These hospitals were  
23 selected for their differing inter-group characteristics, in terms of size, workload,  
24 case-mix and medicines management strategy. The sample size was 6.65% of hospital  
25 activity in England based on the total number of FCEs completed in the year 2001/2

## Antibiotic prescribing indicators

1 (822,445 FCEs from a total of 12,357,360; data obtained from Hospital Episode  
2 Statistics 2001/2 Department of Health, London). A Finished Consultant Episode  
3 (FCE) being defined as ‘a period of healthcare under one Consultant, in one hospital  
4 provider’.<sup>21</sup>

5

6 Antibiotic usage data was collected for systemic antibacterials (ATC category J01).

7

8 The number of occupied beddays and FCEs for each Trust for 2001/2 was recorded  
9 from the Department of Health published Hospital Episode Statistics.

10

11 The hospitals were selected on the basis of their medicines management self-  
12 assessment scores arising from a nationally sponsored self-assessment exercise carried  
13 out at the beginning of 2001.<sup>22</sup> This self-assessment consisted of six equally weighted  
14 domains of activity related to medicines management, with a high score being  
15 indicative of a high degree of control of medicines usage. The maximum possible  
16 aggregate score was 23. The six-domains were as follows –

17

- Senior management awareness and involvement

18

- Information and financial issues

19

- Medicines policy management, including the introduction of new drugs

20

- Procurement of medicines

21

- The primary and secondary care interface

22

- Influencing prescribers

23

24 It was felt that the scores from this exercise would be indicative of the degree of  
25 control and influence over the general use of medicines and more specifically,

## Antibiotic prescribing indicators

1 antibiotics, and that high scores in this measure would be linked to low levels of  
2 antibiotic usage (divergent validity).

3

4 Reviewing the scores for hospitals in the West Midlands, it was possible to select  
5 three high-scoring hospitals (score >19), together with three medium scoring hospitals  
6 (score >15 but < 19) and a third group with lower scores (score <15).

7

8 In addition, to these nine hospitals it was felt that the three English hospitals that have  
9 fully implemented electronic prescribing systems would be used as a discrete  
10 comparator reflecting the potential importance of electronic prescribing systems in  
11 controlling medicines usage. The characteristics of the hospital trusts participating in  
12 the present study are summarised in Table 1.

13

14 In order to validate the medicines management scores which relate to general control  
15 systems in place for all medicines, a questionnaire was designed containing questions  
16 covering 11 aspects of medicines management relating specifically to control of the  
17 use of antibiotics. This ensured consistency in interpretation of the questions across  
18 the sample. The data generated from the questionnaire would also support and cross-  
19 reference the results from the medicines management self-assessment tool. The  
20 questions covered areas of recognised good practice in control of antibiotic usage and  
21 included – audit of usage, data sharing between pharmacy and microbiology  
22 departments, liaison with Infection Control services, pharmacy led educational  
23 initiatives, pharmacist empowerment to convert from IV to oral routes, pharmacist  
24 discontinuation of therapy and rationalisation of formulary choices of antibiotics.

25 The maximum possible score for this assessment was 22.

## Antibiotic prescribing indicators

1 Statistical treatments

2 Data was entered into a flatfield database and analysed using the SPSS version 11  
3 software package.

4

### 5 **Results**

6 Table 2 lists each Trust included in the present study with details of activity, the total  
7 number of DDDs of antibiotic used in 2001/2 and the derived prescribing indicators  
8 and Medicines Management scores.

9

10 The range of Medicines Management scores was from 9 to 22 and the Antibiotic  
11 Management Scores ranged from 2 to 13. The DDD/100 beddays varied from 81.33 to  
12 189.37 (mean 114.62). The DDD/FCE varied from 2.88 to 7.43 (mean 4.1).

13

14 Figure 1 shows the correlation of the two prescribing indicators (Pearson correlation  $r$   
15 = 0.74). Figure 2 shows the correlation of the medicines management scores (Pearson  
16 correlation  $r = 0.74$ ).

17

1 **Discussion**

2 The present study has evaluated the performance of two prescribing indicators, one  
3 established, the other experimental, in assessing antibiotic prescribing in a range of  
4 UK hospital trusts. The DDD/FCE and DDD/100 bedday results did show a  
5 significant correlation ( $r = 0.74$ ). It was felt that this demonstrated the robustness of  
6 the proposed indicator as an additional measure for use when antibiotic drug  
7 utilisation studies are being carried out. This in turn facilitates the identification of  
8 hospitals where more detailed or specialised analysis of antibiotic prescribing is  
9 required.

10

11 The electronic prescribing group had the lowest mean usage 3.5 DDD/FCE. It is likely  
12 that the use of a computerised prescribing system enhances good practice in  
13 prescribing by allowing pre-agreed 'stop dates' to be programmed together with  
14 reminders about reviewing treatment and by providing a greater degree of formulary  
15 control. It would be valuable for a prospective study to be carried out to establish  
16 whether this is the case.

17

18 The total antibiotic usage figures for the twelve hospitals varied from 81.33 – 189.37  
19 DDD/100 beddays (mean 114.6). These findings can be compared with data from  
20 various European studies which found usage at 37.2 – 42.5,<sup>23</sup> 41 – 51<sup>24</sup> and 25-68.<sup>25</sup>  
21 It may be that the much higher rates of antibiotic usage found in this study reflect a  
22 difference in the categories of patients that are included in secondary care activity data  
23 and how the English health care system operates.

24

## Antibiotic prescribing indicators

1 The results do not show an association between a high score in either of the medicines  
2 management scores and a low value for the two prescribing indicators of antibiotic  
3 usage (Table 2). This lack of relationship leads to a conclusion that enhancing  
4 medicines management controls may not reduce antibiotic prescribing. These findings  
5 may indicate that antibiotic prescribing patterns within the study hospitals are subject  
6 to influences not embraced by the indicators employed. Such factors may include the  
7 morbidity of the hospital's catchment population, the casemix of patients treated,  
8 which in turn will be governed by the service profile offered by each hospital in terms  
9 of specialties and number of beds devoted to each specialty.

10

11 A morbidity profile for the catchment population of an individual hospital can be  
12 created from analysis of the Primary Care Trust of residence of patients treated and  
13 linking this to morbidity measures obtained from census data. This work is on-going.  
14 The influence of casemix will influence the WHO measure (DDD/100 beddays) to a  
15 greater degree than the DDD/FCE, since variations in casemix e.g. more surgical  
16 beds, would decrease the average length of stay within a hospital, whilst conversely a  
17 greater proportion of Care of the Elderly beds will generally increase the average  
18 length of stay.

19

20 The FCE is more closely linked to individual in-patient exposure rates to antibiotics  
21 than bedday numbers, as it is a measure of episodes of individual care. However, in  
22 some cases the episode of care may involve a number of Consultants that can lead to  
23 it being counted as more than one FCE.

24

## Antibiotic prescribing indicators

1 It is apparent that additional data is needed before conclusions about the quality of  
2 antibiotic usage in a specific hospital can be drawn. The specific profile of antibiotic  
3 use by therapeutic group for each hospital, together with local bacterial resistance  
4 data, would provide valuable comparative data. This will need to be linked to  
5 morbidity data and the usage data linked to activity will require monitoring over a  
6 number of years in order to determine the effects of controls systems, be they  
7 electronic prescribing systems, utilisation of pharmacists with a remit to change  
8 antibiotic prescribing habits or the establishment of multidisciplinary review teams. In  
9 order to maximise the opportunity for change to occur pharmacists will need to work  
10 closely with microbiologists to influence prescribing habits.

11

12 The Medicines Management self-assessment score (MMAS) and the Antibiotic  
13 Medicines Management score (AMS) showed a high degree of correlation ( $r = 0.74$ ),  
14 which demonstrates that the MMAS is a valid indicator of antibiotic medicines  
15 management arrangements.

16

1 **Conclusion**

2 The WHO indicator for medicines utilisation, DDD/100 beddays, showed the same  
3 level of conformity which was exhibited from the use of the DDD/FCE ( $r = 0.74$ )  
4 indicating that the DDD/FCE is a useful indicator for identifying hospitals which  
5 require further study.

6 The present study has highlighted the following points:

7

- 8 • It is proposed that both the DDD/100beddays and the DDD/FCE are used to  
9 compare antibiotic usage between hospitals in England.
- 10 • The electronic prescribing cohort showed the lowest level of usage  
11 (DDD/FCE) which may indicate the value of computerised prescribing  
12 systems in promoting appropriate antibiotic prescribing.
- 13 • Medicines Management measures are only a single contributor to a hospitals  
14 antibiotic usage profile and may influence quality but not quantity of  
15 antibiotic prescribed.
- 16 • Further work over a number of years is required to establish trends to validate  
17 these results.

18

19

1 **References**

- 2 1. Consumers' Association. (1997). Medicines and the NHS: a guide for  
3 directors. Consumers' Association, London, UK.
- 4 2. National Prescribing Centre. (1999). Hospital Prescribing Information Project,  
5 Second report. Analysis for Health Authority Prescribing Advisers and Senior  
6 Hospital Professionals/Managers. National Prescribing Centre, Liverpool, UK.
- 7 3. Hepler, D. & Strand, L. (1990) Opportunities and responsibilities in  
8 pharmaceutical care. *American Journal of Hospital Pharmacy* **47**, 533-543.
- 9 4. Fitzpatrick, R., Mucklow, J. C. & Fillingham, D. (2001). A comprehensive  
10 system for managing medicines in secondary care. *Pharmaceutical Journal*  
11 **266**, 585-588.
- 12 5. Castle, M., Wilfert, C. M., Cate, T. R. *et al.* (1977). Antibiotic use at Duke  
13 University Medical Centre. *Journal of the American Medical Association* **237**,  
14 2819-2822.
- 15 6. Department of Health (2003). Hospital Pharmacy initiative for promoting  
16 prudent use of antibiotics in hospitals. Department of Health, London, UK.  
17 (PL/PhO/2003/3).
- 18 7. World Health Organization. (2001). WHO Global Strategy for Containment of  
19 Antimicrobial Resistance. World Health Organization, Geneva.
- 20 8. U.S. Congress. (1995). Impacts of Antibiotic-Resistant Bacteria. Office of  
21 Technology Assessment, Washington DC, USA.
- 22 9. Commission of the European Communities. (2001). Council recommendation  
23 on the Prudent use of antimicrobial agents in human medicine. Volume 2, pp.  
24 1-12. Commission of the European Communities, Brussels.

## Antibiotic prescribing indicators

- 1 10. Department of Health. (1999). Resistance to Antibiotics and other  
2 Antimicrobial agents. Department of Health, London, UK. (HSC1999/049).
- 3 11. Department of Health. (2000). UK Antimicrobial Resistance Strategy and  
4 Action Plan, pp. 1-23. Department of Health, London, UK.
- 5 12. Department of Health. (1998). The path of least resistance. Main report of the  
6 Standing Medical Advisory Committee, sub-group on antimicrobial resistance,  
7 pp. 152. Department of Health, London, UK.
- 8 13. Select Committee on Science and Technology. (1998). Resistance to  
9 antibiotics and other antimicrobial agents. House of Lords, Select Committee  
10 on Science and Technology, London, UK.
- 11 14. Gould, I. M. (2001). Minimum antibiotic stewardship measures. *Clinical  
12 Microbiology and Infection* **7**, *Suppl. 6*, 22-26.
- 13 15. Capella, D. (1993). Descriptive tools and analysis. In *Drug utilisation studies.  
14 Methods and uses*, (Dukes, M. N. G., Ed), pp. 55-78. WHO Regional  
15 Publications, WHO Regional Office for Europe, Copenhagen.
- 16 16. United Kingdom Drug Utilisation Research Group. (2000). *Handbook of Drug  
17 Use Research Methodology*, 1st edn, (McGavock, H., ed), pp 255. Prescription  
18 Pricing Authority, Newcastle upon Tyne, UK.
- 19 17. WHO Collaborating Centre for Drug Statistics Methodology. (1999). ATC  
20 Index with DDDs. Oslo, Norway.
- 21 18. Wertheimer, A. I. (1986). The defined daily dose (DDD) system for drug  
22 utilization review. *Hospital Pharmacy* **21**, 233-258.
- 23 19. Wessling, A. & G. Boethius. (1990). Measurement of drug use in a defined  
24 population. Evaluation of the defined daily dose (DDD) methodology.  
25 *European Journal of Clinical Pharmacology* **39**, 207-210.

## Antibiotic prescribing indicators

- 1 20. Curtis, C. E., Fitzpatrick, R. & Marriott, J.F. (2002) An evaluation of  
2 quinolone prescribing in a group of acute hospitals: development of an  
3 objective measure of usage. *Pharmacy World and Science* **24**, 161-166.
- 4 21. Department of Health 2004. HES Factsheet, Glossary of Terms. Department of  
5 Health, London, UK.
- 6 22. Department of Health press release 12 December 2000. Health Minister Lord  
7 Hunt announces new framework to assess medicines management systems in  
8 hospitals. Department of Health, London, UK. (2000/0733).
- 9 23. Janknegt, R., Oude Lashof, A., Gould, I. M. *et al.* (2000). Antibiotic use in  
10 Dutch hospitals 1991-1996. *Journal of Antimicrobial Chemotherapy* **45**, 251-  
11 256.
- 12 24. Kiivet, R. A., Dahl, M. L., Llerena, A. *et al.* (1998). Antibiotic use in 3  
13 European university hospitals. *Scandinavian Journal of Infectious Diseases* 30,  
14 277-280.
- 15 25. Vlahovic-Palcevski, V., Morovic, M., Palcevski, G., Betica-Radic, L. (2001).  
16 Antimicrobial utilization and bacterial resistance at three different hospitals.  
17 *Eur J Epidemiol* **17** (4), 375-383.
- 18

## Antibiotic prescribing indicators

**Table 1. Hospital sites included in the present study**

| <b>Hospital</b> | <b>Comment</b>                                | <b>Number of beds</b> | <b>Cohort</b> |
|-----------------|---|-----------------------|---------------|
| 1               | Urban acute trust                             | 1347                  | A             |
| 2               | Urban acute trust                             | 1330                  | A             |
| 3               | Urban acute trust                             | 811                   | A             |
| 4               | Small town, electronic prescribing            | 465                   | B             |
| 5               | Suburban, electronic prescribing              | 1279                  | B             |
| 6               | County town, electronic prescribing           | 569                   | B             |
| 7               | Urban acute trust                             | 956                   | C             |
| 8               | Urban trust                                   | 634                   | C             |
| 9               | Urban trust<br>(with infectious disease unit) | 1320                  | C             |
| 10              | Suburban trust                                | 503                   | D             |
| 11              | Specialist trust                              | 227                   | D             |
| 12              | County town                                   | 630                   | D             |

Cohort A Medicines Management self assessment score (MMAS) >19

Cohort B Electronic prescribing site

Cohort C Medicines Management self assessment score (MMAS) >15 & <19


Cohort D Medicines management self assessment score (MMAS) <15

Antibiotic prescribing indicators

**Table 2. Summary data 2001/2**


| <b>Hospital<br/>cohort</b> | <b>FCEs</b> | <b>Beddays</b> | <b>DDDs</b> | <b>DDD/<br/>100beddays</b> | <b>DDD/<br/>FCE</b> | <b>Medicines<br/>Management<br/>score<br/>(max 23)</b> | <b>Antibiotic<br/>management<br/>score<br/>(max 22)</b> |
|----------------------------|-------------|----------------|-------------|----------------------------|---------------------|--|---|
| 1 (A)                      | 93626       | 376259         | 413011      | 109.76                     | 4.41                | 20   | 6   |
| 2 (A)                      | 124357      | 339618         | 403806      | 118.9                      | 3.24                | 20   | 11  |
| 3 (A)                      | 72193       | 203178         | 330315      | 162.57                     | 4.57                | 19.5   | 11  |
| 4 (B)                      | 48047       | 142560         | 185511      | 130.1                      | 3.86                | 16   | 11  |
| 5 (B)                      | 97215       | 373071         | 328851      | 88.14                      | 3.38                | 22   | 13  |
| 6 (B)                      | 45225       | 166047         | 152055      | 91.57                      | 3.35                | 16   | 4   |
| 7 (C)                      | 66845       | 263099         | 268607      | 102.09                     | 4.01                | 17.5   | 8   |
| 8 (C)                      | 49856       | 186924         | 173368      | 92.74                      | 3.47                | 17   | 6   |
| 9 (C)                      | 103607      | 406430         | 769661      | 189.37                     | 7.43                | 16   | 3   |
| 10 (D)                     | 54963       | 176542         | 158421      | 89.73                      | 2.88                | 14   | 7   |
| 11 (D)                     | 8984        | 52906          | 43032       | 81.33                      | 4.79                | 9  | 2   |
| 12 (D)                     | 53192       | 173265         | 206543      | 119.2                      | 3.88                | 13   | 3   |

**Figure 1. DDD/100 beddays vs DDD/FCE**



**Pearson correlation  $r = 0.74$ .**

**Figure 2. MMAS vs AMS**



**Pearson correlation  $r = 0.74$ .**